Zimmer Biomet to Acquire Monogram Technologies for $177 Million

Zimmer Biomet has announced a definitive agreement to acquire Monogram Technologies for approximately $177 million, announced in a press release. This acquisition aims to expand Zimmer Biomet's orthopedic robotics suite with Monogram's semi- and fully autonomous robotic technologies.

The transaction, unanimously approved by both companies' boards, involves an upfront payment of $4.04 per share in cash and a contingent value right (CVR) that could provide additional payments if certain milestones are met by 2030. Monogram's technologies are expected to enhance Zimmer Biomet's ROSA Robotics platform, particularly in total knee arthroplasty (TKA) procedures.

Monogram's AI-navigated TKA robotic technology, which received FDA clearance in March 2025, is set to be commercialized with Zimmer Biomet implants by early 2027. The acquisition is anticipated to be neutral to Zimmer Biomet's adjusted earnings per share from 2025 to 2027 and accretive thereafter, contributing to revenue growth starting in 2027. The deal is expected to close later this year, pending regulatory and stockholder approvals.